Cell Culture Media Market in terms of revenue was estimated to be worth $6.2 Billion in 2023 and is poised to reach $13.0 Billion by 2028, growing at a CAGR of 16.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of the market is majorly attributable to increased demand for biosimilars and mAbs globally, rising investment & funding for stem cell research, focus of key market players on launch of novel products in the market.
Download an Illustrative overview:
Browse in-depth TOC on "Cell Culture Media Market"
359 - Tables
42 - Figures
315 – Pages
In 2022, the serum-free media segment accounted for the largest share of the type segment in the cell culture media industry.
On the basis of type, the cell culture media market is divided into serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2022, the serum-free media segment holds for the bigest share of the market. Factors responsible for the growth of this segment includes various advantages or benefits of serum-free media over other types of cell culture media.
In 2022, the biopharmaceutical production segment accounted for the largest share of the application segment in the cell culture media industry.
On the basis of application, the cell culture media market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is estimated to grow at the highest growth rate during the forecast period. Factors responsible for the growth include, the growing production of cell culture-based vaccines, and expansion of pharmaceutical industry. The biopharmaceutical production applications of cell culture media include the manufacturing of biologic-based products such as vaccines, monoclonal antibodies, and other therapeutic proteins (such as anticoagulants, enzymes, blood factors, hormones, interferons, growth factors, interleukins, engineered proteins, and thrombolytics, among others).
In 2022, the Asia Pacific region is the fastest-growing region of the cell culture media industry.
On the basis of the region, the global cell culture media market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. During the forecast period, the Asia Pacific market is estimated to register the highest CAGR during the forecast period. Increased focus of key market players on geographical expansion in emerging markets, favorable government policies and support for cell-based vaccines in the region and less manufacturing cost are some of the major factors anticipated to have positive impact on the market growth of Asia Pacific region.
Request Sample Pages:
Cell Culture Media Market Dynamics:
Drivers:
Increasing demand for serum and animal component-free media
Restraints:
Expensive cell biology research products
Opportunities:
Increasing incidence of infectious diseases and outbreaks of pandemics
Challenges:
Survival of small players and new entrants
Key Market Players:
Key players in the cell culture media market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Irvine Scientific, Inc. (Japan), Lonza Group AG (Switzerland), Becton, Dickinson and Company (US), Miltenyi Biotec (Germany), and among others.
Recent Developments:
In June 2023, Thermo fisher launched Tumoroid Culture Medium to accelerate development of novel cancer therapies.
In April 2023, FUJIFILM Irvine Scientific launched BalanCD CHO Media Platform Portfolio for Bioprocessing.
In March 2022, FUJIFILM Irvine Scientific acquired Shenandoah Biotechnology. The deal would help the company to provide customers with a single point of access for their life science research, discovery, and cell and gene therapy needs.
In January 2022, Cytiva and Nucleus Biologics LLC collaborated to enhance custom cell media development for cell and gene therapies.
Get 10% Free Customization on this Report:
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Related Reports:
Regenerative Medicines Market: Regenerative Medicine Market in terms of revenue was estimated to be worth $16.0 billion in 2023 and is poised to reach $49.0 billion by 2028, growing at a CAGR of 25.1% from 2023 to 2028
Synthetic Stem Cells Market: The Synthetic Stem Cells Market size is expected to grow from USD 14 million in 2023 to USD 37 million by 2028, at a CAGR of 22.5% during the forecast period.
Comentarios